Conferences
Breast Cancers
GI Cancers
Gynecologic Cancer
Immunology News
Multiple Myeloma
Hematology
Lymphoma
Leukemia
Lung Cancers
Melanoma
Prostate Cancer
Urology
CLL
Precision Medicine
Supportive Care
More...
Giants Cancer Care

Dr. Beer on the Implications of the PREVAIL Study

Tomasz Beer, MD, FACP
Published Online: Monday, February 3, 2014
Tomasz Beer, MD, FACP, professor of Medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, discusses the treatment of metastatic castration-resistant prostate cancer (mCRPC) with abiraterone and enzalutamide as it relates to results from the PREVAIL study.

Beer says that is a wonderful time to contemplate how two effective drugs could both be used for patients in this space. As the PREVAIL study was not designed to compare abiraterone and enzalutamide, it cannot be said that one drug is superior or inferior.

A decision to treat with abiraterone or enzalutamide must be made on a physician-by-physician and patient-by-patient basis as there are specific considerations to be made. For example, Beer notes, enzalutamide does not require steroids, so for patients for whom giving steroids is a concern, enzalutamide may be preferred.

Beer says that there are many differences in the two studies and the data that may help a physician make decisions.

<<< View more from the 2014 GU Cancers Symposium



Online CME Activities
Free CME from PER
Advances in Multiple Myeloma
Cancer Summaries and Commentaries™: Update from Chicago: Castrate Resistant Prostate Cancer and Advanced Melanoma
Community Practice Connections™: Novel Perspectives in Personalizing EGFR-Targeted Therapy in NSCLC: Frontline and Overcoming Resistance
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Gynecologic Cancers
More Reading
 
$auto_registration$